The Characters Of PDCD4 Expression In Patients With Polycystic Ovary Syndrome And The Effect Of Drug Therapy

Purpose of the study:To investigate the relationship between PCOS and PDCD4 expression in women of childbearing age by studying the correlation of Glucose and Lipid Metabolism and PDCD4 expression in PCOS patients with PCOS with Ir,the expression of PDCD4 in patients with polycystic ovary syndrome.Methods:A total of 80 PCOS patients aged 20-35 with PCOS IR who attended the Department of endocrinology and metabolism in Tianjin Medical University from November 2018 to March 2020 were selected.According to BMI and treatments,,80 patients with PCOS were randomly divided into obese group(≥25 kg/ ㎡,Group A and B)and non-obese Group(BMI < 25 kg/ ㎡,Group C and D).There were 20 patients in Group A and 20 patients in Group C treated with metformin tablets(oral)as control group,20 patients in Group B and 20 patients in Group D treated with pioglitazone metformin tablets(oral)as observation group.All patients were followed up and monitored.All patients were measured for height and weight.All women were measured for height and weight on the day of blood sampling to calculate BMI.Height measurement was accurate to 0.1 m and barefoot was required The weight measurement was accurate to 0.1 kg.All the women were taken venous blood under the condition of fasting on the 2nd ~ 3rd day of the Menstrual Cycle after the natural menstrual cycle or luteal phase withdrawal.Some of the blood was used for serological detection to determinate the levels of reproductive hormone,including follicle stimulating hormone(FSH),luteinizing hormone(LH),thyroid-stimulating hormone(TSH)and testosterone(T),and some of the whole blood was separated for peripheral blood mononuclear cells(PBMC)separation,for real-time quantitative PCR testing.Total cholesterol,triglyceride,high-density Lipoprotein and Low-density Lipoprotein were measured by chemiluminescence.The Fasting Blood Glucose,fasting serum insulin and 120 min after taking glucose were measured by chemiluminescence method.Homeostasis modeling index(HOMA-IR)and Islet Cell Function Index(HOMA-IR)were calculated.Finally,each group of clinical data,the corresponding statistical analysis,and finally draw the relevant conclusions.Results:1.The expression of PDCD4 in Obese Group was significantly higher than that in non-obese group in PCOS,and there was significant difference(p < 0.001).2.There was a positive correlation between PDCD4 expression and BMI in PCOS patients(r =0.53,p< 0.001).3.The expression of PDCD4 was significantly correlated with Insulin 0,Insulin120,Glucose120,HOMA-IR and HOMA-IR in women with PCOS(r=0.35,0.30,0.28,0.37,0.24;p<0.01);The expression of PDCD4 in PBMCs was significantly decreased after administration of the drug,pioglitazone and metformin tablets were significantly lower than metformin tablets alone(p< 0.05).4.There was a positive correlation between the expression of PDCD4 and TG in PCOS patients(r=0.38;p< 0.001),but there was a negative correlation between the expression of PDCD4 and HDL(r=-0.42;p< 0.001).5.In the pioglitazone-metformin group,there were 3 cases of mild diarrhea symptoms.In the metformin group,there was 1 case of mild nausea symptoms.No patients had hypoglycemia symptoms or lactic acidosis,there were no significant changes in liver and kidney function before and after treatment,while the incidence of adverse events(7.5%,2.5%).Conclusion:1.The expression of PDCD4 was high in PCOS patients,and increased significantly in obese patients;2.In patients with PCOS,the high expression of PDCD4 was associated with BMI,Ir and Lipid metabolism disorder,and was a risk factor for PCOS.After treatment with pioglitazone,metformin and Metformin,the expression of PDCD4 was decreased,the former reduces more obviously,may reduce the patient’s insulin sensitivity significantly.